Quantcast
Last updated on April 19, 2014 at 7:46 EDT

Latest Humanized antibody Stories

2008-07-24 12:01:22

ImmunoCellular Therapeutics, a biotechnology company, has signed a research agreement with UK-based biotechnology company Antitope for the humanization of IMUC's monoclonal antibodies. ImmunoCellular Therapeutics (IMUC) is advancing its monoclonal antibodies toward clinical trials, and humanizing the antibodies will provide for a safer therapeutic with less immunogenicity potential. IMUC, through its recent acquisition of monoclonal antibody-related technology from Molecular Discoveries,...

2008-07-17 09:01:20

ROCKVILLE, Md., July 17 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced the acquisition of Raven Biotechnologies, Inc., a privately held biotechnology company in South San Francisco, California, focused on the discovery and development of monoclonal antibody therapeutics for oncology through its cancer stem cell program. Raven has developed a portfolio...

2008-07-15 09:01:35

Medical Research Council Technology and Biolex Therapeutics have announced that MRCT has successfully completed the humanization of a novel antibody targeting CD20, indicated in non-Hodgkin's lymphoma and rheumatoid arthritis. Biolex is applying its proprietary glycosylation optimization technology to the antibody, BLX-301, to enhance efficacy and potency of the product candidate and potentially reduce certain side effects. Biolex will retain all development and commercialization rights...

2008-07-15 09:01:35

BERKELEY, Calif., July 15, 2008 (PRIME NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, today announced that results from two ongoing Phase 1 studies of XOMA 052 in Type 2 diabetes will be presented at the 44th European Association for the Study of Diabetes (EASD) Annual Meeting that will be held in Rome, Italy on September 7-11, 2008. The oral presentation, titled "XOMA 052, an Anti-IL-1beta Antibody, in a Double-Blind,...

2008-07-14 09:01:11

MRC Technology (MRCT) (London, UK) and Biolex Therapeutics, Inc. (Pittsboro, North Carolina, USA) announced today that MRCT had successfully completed the humanization of a novel antibody targeting CD20, indicated in non-Hodgkin's lymphoma and rheumatoid arthritis. Biolex is applying its proprietary glycosylation optimization technology to the antibody, BLX-301, to enhance efficacy and potency of the product candidate and potentially reduce certain side effects. "We are delighted to have...

2008-06-24 06:01:08

NEW YORK, June 24 /PRNewswire-FirstCall/ -- Intellect Neurosciences, Inc. (BULLETIN BOARD: ILNS) and MRC Technology (MRCT) announced today they have achieved an important milestone through their collaborative efforts to humanize Intellect's lead antibody IN-N01 necessary for creating a therapeutic antibody for the treatment of Alzheimer's disease. The antibody is intended to be used to promote clearance from the brain of beta amyloid, the toxin that leads to Alzheimer's disease. IN-N01...

2008-06-19 09:00:09

Immunomedics has presented promising preclinical results on pretargeted therapy of pancreatic cancer that can be further improved when given in small fractions repeatedly, and in combination with gemcitabine. The pretargeted therapy involved TF10, a humanized bispecific antibody that binds to the same pancreatic cancer mucin as the antibody PAM4. TF10 was created by the company's protein engineering platform technology known as Dock-and-Lock, developed with scientists of IBC...

2008-06-16 12:00:00

NEW ORLEANS, La., June 16, 2008 (PRIME NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported that pretargeting with a bispecific antibody (bsMAb) and a peptide labeled with gallium-68 (Ga-68), a positron emission tomography (PET) sensitive radioisotope, produced excellent images in a human colorectal cancer model. The bsMAb used in this study was TF2, an antibody...